Organisation paid for research Program year 2025 Source: CMS Open Payments

CTMD Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,899,849

148 payments

Through program year 2025, CTMD Research Inc is reported as receiving $1,899,849 in research payments, across 148 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$94,888	23
2024	Research	$34,110	5
2023	Research	$796,965	35
2022	Research	$103,534	11
2021	Research	$93,914	14
2020	Research	$776,438	60

Breakdown

Who paid Research payments · program years 2020–2025

Becton, Dickinson and Company $1,350,003 5 payments
GlaxoSmithKline, LLC. $423,844 125 payments
Pfizer Inc. $101,303 10 payments
Gilead Sciences, Inc. $12,864 1 payment
Regeneron Pharmaceuticals, Inc. $11,836 7 payments

Studies the money was for Research payments · program years 2020–2025

Triplex $713,691 1 payment
Veritor Antigen Assay $625,827 2 payments
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO $282,021 90 payments
A Phase 3B, Open-Label, Single-Arm Study in Adolescent and Adult Femal $59,417 11 payments
A Phase 3 Randomized Doubleblind Placebocontrolled 26Week Multicenter Study With A 78Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Mo $56,031 6 payments
A Phase 2A Randomized Doubleblind Placebocontrolled 3Arm Parallel Group Study to Evaluate Safety Tolerability and Pharmacodynamics of Pf06835919 Administered Daily for 16 Weeks in Adults With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus on Metformin $45,272 4 payments
A Phase 4, 52-Week (Primary Analysis at 24-Weeks), Randomized, Stratif $41,721 13 payments
A Phase 1, Single-Blind, Safety, Reactogenicity, and Immunogenicity Tr $21,435 8 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multic $19,250 3 payments
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $12,864 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.